TQ Quiz | Identifying and Managing Pharmaceutical Complications (Nashville 2025) by Events@optometricedu.com | Oct 22, 2025 | 2025 Nashville, TQ Courses | 0 comments "*" indicates required fields This field is hidden when viewing the formDate (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent Date (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent 90 days past date (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent Date Difference (Hidden)1. What is the name of the FDA’s safety information and adverse event reporting program?* A - MedWatch B - MedCheck C - DrugDatabase D - DrugAudit 2. Which of the following medications is most likely to increase risk of iris prolapse during cataract surgery?* A - Amiodarone B - Flomax C - Lipitor D - Viagra 3. A possible adverse effect during atorvastatin (Lipitor) treatment is:* A - Cystoid macular edema B - Retinal artery occlusion C - Retinal detachment D - Choroidal neovascularization 4. A 25-year old male presents for an annual comprehensive eye examination with no report of visual concerns or changes to vision. He currently takes multiple systemic medications. Entering visual acuity is 20/20 OD and OS and anterior segment examination is unremarkable. You observe bilateral optic disc edema. Which of the following medications is most likely to be the culprit, assuming no underlying systemic etiology?* A - Azithromycin B - Topiramate C - Cetirizine D - Tetracycline 5. Plaquenil (hydroxychloroquine) toxicity results in which of the following ocular findings?* A - Abnormality to the inner segment/outer segment junction of photoreceptors B - Optic disc edema C - Epiretinal membrane formation D - Increased intraocular pressure 6. During a comprehensive eye examination, you observe bilateral whorl keratopathy (corneal verticillata) in a 70-year old female which you believe is secondary to amiodarone use. No other ocular abnormalities are noted. What is the most appropriate management plan for this patient?* A - Advise the patient to discontinue to medication immediately. Write and send a letter to the managing physician communicating your findings and management plan. Schedule the patient for follow up in one month. B - Urgently telephone the patient’s managing physician recommending that they advise the patient to discontinue to medication immediately. Schedule the patient for follow up in one week. C - Write and send a letter to the patient’s managing physician communicating your findings, recommending that the patient continue the medication as prescribed. Schedule the patient for follow up in one year. D - Considering this is not a vision-threatening findings, communication with the patient’s managing physician is not advised. Schedule the patient for follow up in one year. 7. Based on your clinical examination, you suspect pseudotumor cerebri in a 16-year old female who has been taking an oral contraceptive agent for 2 years. What clinical finding did you observe?* A - Bilateral cystoid macular edema B - Bilateral anterior uveitis C - Bilateral optic disc edema D - Bilateral elevated intraocular pressure 8. A 21-year old male patient who is taking multiple medications presents for evaluation of sudden onset blurred near vision and light sensitivity. You measure each pupil to be 8mm in diameter in bright light. His posterior segment examination is unremarkable. Which medication is the most likely cause of his symptoms?* A - Diphenhydramine B - Tylenol with codeine #3 C - Hydroxychloroquine D - Isotretinoin 9. Long-term safety of an approved and marketed drug may be formally assessed in a:* A - Phase one clinical trial B - Phase two clinical trial C - Phase three clinical trial D - Phase four clinical trial 10. Long-term, high-dose oral NSAIDs increase the risk of which of the following events?* A - Osteoporosis B - Myocardial infarction C - Bipolar disorder D - Weight gain 11. What is the primary purpose of the FDA Adverse Event Reporting System (FAERS)?* A - To prescribe medications B - To track and analyze adverse drug reactions C - To develop new medications D - To regulate clinical trials 12. Which of the following patients should be cautioned regarding the risk of acute angle closure crisis while taking an oral antihistamine?* A - A 55-year old with primary open angle glaucoma B - A 55-year old with ocular hypertension C - A 55-year old primary angle closure suspect D - A 55-year old with pigmentary glaucoma 13. A 42-year old female presents for comprehensive eye examination with no ocular concerns. Pupils are measured to be 2mm in dim illumination with minimal reactivity and no afferent pupillary defect. She reports no systemic medications, but is recovering from recent spinal fusion surgery. Which of the following medications may be cause the observed finding?* A - Acetaminophen B - Ibuprofen C - Aspirin D - Hydrocodone 14. Cannabidiol (CBD) oil may exhibit which ocular effect?* A - Increased intraocular pressure B - Decreased intraocular pressure C - Increased myopia D - Decreased myopia 15. Which of the following systemic conditions is a contraindication to the use of acetaminophen?* A - Liver disease B - Hypertension C - Diabetes mellitus D - Asthma 16. Chronic use of a steroid nasal spray may result in:* A - Elevated intraocular pressure B - Cystoid macular edema C - Retinal detachment D - Optic neuritis 17. Ethambutol may be prescribed for treatment of which infectious condition?* A - Syphilis B - Tuberculosis C - Lyme disease D - Measles 18. Which of the following individuals is at greatest risk of hydroxychloroquine retinal toxicity?* A - An individual taking 7mg/kg/day of hydroxychloroquine B - An individual who is taking ibuprofen in addition to hydroxychloroquine C - An individual with low red blood cell count D - An individual with a history of intolerance to methotrexate 19. Warfarin use increases the risk of which ocular finding?* A - Subconjunctival hemorrhage B - Acute angle closure crisis C - Anterior uveitis D - Cranial nerve palsy 20. For patients receiving Elahere (mirvetuximab soravtansine-gynx injection) in the treatment of ovarian cancer, how often should patients be evaluated for the development of adverse ocular effects?* A - Every cycle (every 3 weeks) B - Every other cycle (every 6 weeks) C - Daily while undergoing therapy D - No specific monitoring guidelines exist Personal InformationName* First Last Email* Phone*OE Tracker #License #Address* Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussian FederationRwandaRéunionSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTaiwanTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkmenistanTurks and Caicos IslandsTuvaluTürkiyeUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Payment InformationPromotional CodeNashville 2025 - Identifying and Managing Pharmaceutical Complications*After 90 days, pricing will increase to $30. Price: Retake Discount Price: Promotional Discount Price: Credit Card* This field is hidden when viewing the formCourse Information (HIDDEN)This field is hidden when viewing the formCourse Name (HIDDEN)This field is hidden when viewing the formRetake Code (HIDDEN)This field is hidden when viewing the formQuiz URL (HIDDEN)Do not include ending backslash (aka no .com/)This field is hidden when viewing the formCE Hours Submit a Comment Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website
